Atrial Fibrillation Ablation: Efficacy and Safety in Acute and Long-Term Follow up of NmarqTM and ThermocoolR Catheters

Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population [1]. Current guidelines recommend catheter ablation of AF in symptomatic patients after failure or intolerance of antiarrhythmic drugs [2,3]. The pathogenesis of AF is complex, but several studies reported that Pulmonary Vein (PV) foci play a critical role in both initiation and perpetuation of this arrhythmia. PV isolation, therefore, is the cornerstone of catheter ablationin AF treatment [2,3].